Chinese Cancer‑Ablation Tools Are Winning Over the World

Chinese companies that make devices to destroy tumors are no longer selling cheap copies – they’re exporting breakthrough technology. In the past, firms relied on low prices to get into overseas hospitals, but today foreign distributors are lining up to partner with Chinese innovators. The shift is driven by solid clinical data. For example, Nuosheng Medical’s high‑frequency irreversible electroporation (H‑FIRE) system cut the rate of significant prostate cancer to just 6 % after six months, while preserving urinary control in 97 % of patients and sexual function in 91 %. A study of 1,452 patients was published in JAMA Surgery, and the European Association of Urology now lists this technique as an A‑level recommendation. Similarly, Haieya’s Kangbo Knife, which combines cryo‑hyperthermia with immunotherapy, more than doubled progression‑free survival in a trial reported in the high‑impact journal Signal Transduction and Targeted Therapy. Other firms such as RuiDi Bio, Daoyang Medical and GaineWei Medical are showcasing devices that target hard‑to‑treat cancers with precision and minimal side effects. These successes have led to invitations to major conferences, live surgical demos, and visits from health officials worldwide. The result: Chinese tumor‑ablation tools are now seen as premium, evidence‑backed solutions that improve patient outcomes and are reshaping global medical standards.

Read more